Publications by authors named "E Azambuja"
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use of PPIs affected survival outcomes in patients treated with palbociclib in PALLAS.
View Article and Find Full Text PDFBackground: In HER2+ early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology and prognostic implications across 4 neoadjuvant studies of trastuzumab with or without lapatinib, and with or without chemotherapy: CALGB 40601, PAMELA, NeoALTTO and NSABP B-41.
Patients And Methods: We compared tumor and immune gene expression changes during neoadjuvant treatment and their association with with event-free survival (EFS) by uni- and multivariable Cox regression models in different cohorts and timepoints: 452 RD samples at baseline including 169 with a paired RD, and biomarker changes during neoadjuvant therapy, evaluating model performance via the c-index.
Results: Analysis of 169 paired tumor samples revealed a shift in intrinsic subtype proportions from HER2-Enriched at baseline (50.
Article Synopsis
- - Patients with HER2-positive breast cancer face a high risk of brain metastases, impacting their survival and quality of life, and there is a need for better primary prevention strategies.
- - Experts developed consensus statements through a modified Delphi process to address current unmet needs and assess available evidence on brain metastases management.
- - Out of 55 statements reviewed by contributors, 34 achieved consensus regarding areas like prevention, screening, and treatment efficacy, while some statements lacked agreement due to insufficient evidence; these consensus statements can guide clinical practice and future research.
Article Synopsis
- Recent advancements in antibody-drug conjugates (ADCs) have improved outcomes for patients with HER2-low-expressing breast cancer, a group that previously lacked effective targeted therapies.
- A systematic review and meta-analysis was conducted to evaluate the effectiveness of various ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in treating HER2-low advanced or metastatic breast cancer, pulling data from multiple reputable sources.
- The findings revealed that patients treated with T-DXd had significantly better outcomes in terms of objective response rate, disease control rate, and overall survival compared to those receiving traditional treatment options, highlighting the potential of ADCs as effective therapies.